Batiraxcept

{
  "id": "MLC-T-ONC-011887",
  "term": "Batiraxcept",
  "field": "Oncology and biomedicine",
  "definition": "A soluble fusion protein comprised of the extracellular domain of the receptor tyrosine kinase (RTK) AXL (UFO) fused to a human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic activity. Upon administration, batiraxcept selectively binds to growth arrest-specific protein 6 (GAS6), the endogenous ligand for AXL. This may inhibit GAS6/AXL-mediated signaling, which plays a key role in tumor cell proliferation, survival, invasion and metastasis, as well as immune evasion and resistance to other anticancer agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of RTKs, is overexpressed by many tumor cell types and its expression is associated with drug resistance and poor prognosis.",
  "synonyms": [
    "AXL Fc fusion protein AVB-S6-500",
    "anti-AXL fusion protein AVB-S6-500",
    "RUGA-S6"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/batiraxcept/"
}